Latest Distribution Channels News

Turners Automotive Group has posted a record $63.2 million normalised NPBT for FY26, advancing its $65 million NPBT target to FY27 and setting sights on $100 million by FY31 amid solid finance and retail momentum.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Renowned boosts its US footprint with a landmark RE/MAX partnership and expands multi-year brokerage deals in Australia and New Zealand, driving 3% group revenue growth and positive cash flow in Q3 FY26.

GCM Corporation finalises exclusive rights to its Very High Density technology, launches its first commercial heat sink products, and expands global prototyping efforts targeting high-growth sectors including EV infrastructure and data centres.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Biome Australia’s Activated Probiotics brand surpasses one million boxes sold in Australia, approaches top pharmacy ranking, and launches nationally in Canada, setting the stage for FY26 profitability.

First Graphene has secured advanced graphene coatings technology through the AU$250,000 acquisition of Ionic Industries and Imagine Intelligent Materials, gaining immediate entry into lucrative geotextile and environmental infrastructure sectors.

Butn Limited has signed a memorandum of understanding with a major global bank to launch buyer-led supply chain finance programs in Australia, leveraging Butn’s proprietary platform and the bank’s funding capacity.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

Sarytogan Graphite Limited has upgraded its Central Graphite Zone resource, marking a key milestone with Measured classification and progressing its Definitive Feasibility Study. Meanwhile, copper exploration reveals promising anomalies, backed by fresh capital injections.

N1 Holdings delivered record settlement volumes and a 127% surge in quarterly cash receipts despite challenging market conditions, driven by disciplined funding and operational efficiency.